Health Care Innovation
Commentary
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Blog
Despite High Costs, Americans Support Potential of Innovative Gene Therapies to Cure Difficult-to-Treat Diseases
SAN FRANCISCO – A new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI), shows that Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses. Click here to read the top-line results of PRI’s poll on gene therapies ...
Health Care
Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief
The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical ...
Commentary
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Commentary
Don’t Legislate Away Biopharmaceutical Innovation
The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
Blog
“HELP-ing” to Make Health Care More Affordable
The Senate Health, Education, Labor & Pensions (HELP) Committee has just released a bi-partisan bill authored by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) that would make health care more affordable and more transparent for patients. These reforms are not grandiose fantasies that are destined to fail, such as ...
Commentary
Differentiating Health Care Costs from Health Care Value
The wrong model, no matter how hard you work it, will never provide the right answer. When it comes to how we pay for health care, the U.S. is using the wrong model. What’s worse, these financing inadequacies could threaten the viability of new therapies that will bring hope to ...
Health Care
Read Sally Pipes in Heartland News Story on Telemedicine
Telemedicine Offers Remedy for Rising Travel and Wait Times By Leo Pusateri Travel and wait times for health care cost patients $89 billion annually, according to an analysis by Altarum, giving new vigor to legislative arguments supporting telemedicine. Patients travel an average of 34 minutes for health care and wait ...
California
The Perils of Regulating Drugs by Sound Bite
There is a legal adage that “hard cases make bad law.” California may soon rediscover this wisdom. Assembly member Jim Wood has introduced a bill (AB 824) with the intention of discouraging “pay-for-delay” tactics. “Pay-for-delay” practices refer to a situation when a manufacturer of a patented drug pays the manufacturer ...
Commentary
Price Controls by Another Name
The costs of medicines continue to dominate the headlines, attracting the attention of Congress and the Trump Administration. Reforms are necessary, but many of the reforms under consideration will make the situation worse. Indexing U.S. prices to the prices in other countries that use price controls, or using third-party arbitration ...
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Despite High Costs, Americans Support Potential of Innovative Gene Therapies to Cure Difficult-to-Treat Diseases
SAN FRANCISCO – A new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI), shows that Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses. Click here to read the top-line results of PRI’s poll on gene therapies ...
Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief
The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical ...
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Don’t Legislate Away Biopharmaceutical Innovation
The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
“HELP-ing” to Make Health Care More Affordable
The Senate Health, Education, Labor & Pensions (HELP) Committee has just released a bi-partisan bill authored by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) that would make health care more affordable and more transparent for patients. These reforms are not grandiose fantasies that are destined to fail, such as ...
Differentiating Health Care Costs from Health Care Value
The wrong model, no matter how hard you work it, will never provide the right answer. When it comes to how we pay for health care, the U.S. is using the wrong model. What’s worse, these financing inadequacies could threaten the viability of new therapies that will bring hope to ...
Read Sally Pipes in Heartland News Story on Telemedicine
Telemedicine Offers Remedy for Rising Travel and Wait Times By Leo Pusateri Travel and wait times for health care cost patients $89 billion annually, according to an analysis by Altarum, giving new vigor to legislative arguments supporting telemedicine. Patients travel an average of 34 minutes for health care and wait ...
The Perils of Regulating Drugs by Sound Bite
There is a legal adage that “hard cases make bad law.” California may soon rediscover this wisdom. Assembly member Jim Wood has introduced a bill (AB 824) with the intention of discouraging “pay-for-delay” tactics. “Pay-for-delay” practices refer to a situation when a manufacturer of a patented drug pays the manufacturer ...
Price Controls by Another Name
The costs of medicines continue to dominate the headlines, attracting the attention of Congress and the Trump Administration. Reforms are necessary, but many of the reforms under consideration will make the situation worse. Indexing U.S. prices to the prices in other countries that use price controls, or using third-party arbitration ...
